From NAFLD to NASH: Is Inflammation the Culprit?

Stephen A. Harrison, MD, an expert in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), discusses the role of inflammation in the worsening of NAFLD to NASH from the Spring 2023 Cardiometabolic Health Congress (CMHC) in Orlando. *Editorial note: on May 19, 2023, the FDA AdCom (advisory committee) voted against the approval of obeticholic acid for NASH.
Recorded on May 19, 2023.